埃克替尼治疗EGFR突变型非小细胞肺癌脑转移的预后

Prognosis of icotinib for brain metastases in EGFR mutated non-small cell lung cancer

目的:探讨埃克替尼治疗EGFR突变型非小细胞肺癌脑转移的临床效果及预后因素.方法:回顾性分析2012年1月至2015年9月诊断肺癌脑转移并接受埃克替尼治疗的116例患者.采用Kaplan-Meier单因素、Cox多因素分析方法,探讨非小细胞肺癌脑转移患者接受埃克替尼治疗的生存情况及影响因素.结果:116例非小细胞肺癌脑转移患者以女性、<60岁和不吸烟患者为主.Cox风险比例回归模型显示:病理类型和EGFR基因类型是非小细胞肺癌脑转移患者接受埃克替尼治疗的独立预后因素.结论:非小细胞肺癌脑转移患者接受埃克替尼治疗具有良好的疗效,腺癌亚型患者的PFS和OS均长于非腺癌患者,EGFR常见突变患者PFS和OS均长于少见突变.

Objective:To investigate the efficacy and survival analysis icotinib treatment for brain metastasis in non-small cell lung cancer patients with EGFR mutation. Methods:We retrospectively reviewed non-small cell lung cancer patients with brain metastases who were treated with icotinib, and the survival rate was calculated by Kaplan- Meier method and log-rank test was used to compare the survival rates. Univariate and multivariate factors for survival were analyzed by Cox proportional hazards regression model. Results:A total of 116 cases of rain metastases in EGFR mutated non-small cell lung cancer were female, less than 60 years old and non-smoking patients predominant;Cox multivariate analysis found that histologic subtype and EGFR gene subtype were independent prognostic factors for these patients. Conclusion:Icotinib showed promising efficacy in NSCLC patients with brain metastases. PFS and OS was longer in patients with adenocarcinoma than in those with a non-adenocarcinoma subtype. PFS and OS was longer in patients with EGFR common mutations than EGFR uncommon mutations.